A phase 2-3 clinical trial is testing whether an existing heart drug, eplerenone, can stop or slow heart damage in Duchenne muscular dystrophy

posted on June 29, 2012 - 6:00am
Eplerenone, a drug commonly used to prevent scarring after a heart attack, is being tested in a phase 2-3 clinical trial to determine whether it can stop or slow heart damage in people with Duchenne muscular dystrophy (DMD).   Eplerenone blocks scarring that over time can turn heart muscle into nonfunctioning fatty tissue.

New content is being added every day. Please check back again.